BAYER REMAINS NUMBER ONE ASPIRIN BRAND WITH 22% SHARE
This article was originally published in The Tan Sheet
BAYER REMAINS NUMBER ONE ASPIRIN BRAND WITH 22% SHARE in the U.S., SmithKline Beecham noted in acquisition background materials. Sales for the Bayer brand in the U.S., including the two-year-old Bayer Select line of analgesics, were $132.1 mil. in the 12 months through March, based on Towne-Oller data. In the U.S., SB's analgesic presence is limited to Ecotrin enteric-coated aspirin.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC